Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹255 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Archean Chemical Industries reported a mixed Q3 FY26 with standalone revenue growing 12% YoY, but EBITDA declined 25% YoY to ₹69.9 crore, and PAT fell to ₹34.3 crore. Industrial salt volumes recovered to 1.1 million tons, while bromine production remained constrained by operational issues, with a backlog of 6,500 tons. Bromine derivatives utilization is at 30-40%, with a target to reach 60-70% in FY27. SOP pilot trials are complete, with plant-scale trials expected in Q4. The semiconductor project (Systm) is progressing, with land allocation and groundbreaking completed. Risks include persistent delays in SOP and derivatives ramp-up, and potential margin pressure from rising bromine costs. Management acknowledged execution challenges but expressed confidence in recovery by FY27.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects to scale up bromine derivatives utilization from current 30-40% to 60-70% by end of FY27, driven by new product pipeline and customer approvals.
- Management stated they will be 'north of 18,000 tons' of bromine production next year, recovering from operational disruptions.
- SOP pilot trials successful; plant-scale trials to commence in Q4 FY26, with meaningful revenue expected in second half of FY27.
- The flame retardant bromine project is under evaluation but remains on track for a 12-18 month timeline from Q2 FY26, targeting end of FY27.
Risks flagged
- SOP and bromine derivatives have faced repeated delays; management acknowledged being 12-18 months behind on derivatives. Further delays could impact FY27 revenue expectations.
- Operational disruptions from erratic monsoons and brine quality changes have constrained bromine output. While fixes are implemented, recurrence could limit volume growth.
- Increasing bromine prices are squeezing margins in the derivatives segment as cost pass-through is limited. This could persist if bromine prices remain elevated.
- The Systm semiconductor project depends on finalizing a fiscal support agreement with the Indian Semiconductor Mission, which has no clear end date. Delays could push back revenue generation.
Key quotes
- We are probably 12 to 18 months behind... a lot of this has just been how quickly we execute here.
- Our conviction on SOP still remains extremely strong... it is a complex technical problem which takes time to solve.
- We will be north of 18,000 tons next year.
Research modules